BioXcel Therapeutics (BTAI) Competitors $2.20 -0.10 (-4.13%) As of 02:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BTAI vs. PRTC, ALT, CDXC, KMDA, MREO, ERAS, TKNO, SIGA, SAGE, and ZVRAShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include PureTech Health (PRTC), Altimmune (ALT), ChromaDex (CDXC), Kamada (KMDA), Mereo BioPharma Group (MREO), Erasca (ERAS), Alpha Teknova (TKNO), SIGA Technologies (SIGA), Sage Therapeutics (SAGE), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. PureTech Health Altimmune ChromaDex Kamada Mereo BioPharma Group Erasca Alpha Teknova SIGA Technologies Sage Therapeutics Zevra Therapeutics BioXcel Therapeutics (NASDAQ:BTAI) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Do analysts rate BTAI or PRTC? BioXcel Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 1,508.70%. PureTech Health has a consensus target price of $45.00, suggesting a potential upside of 144.11%. Given BioXcel Therapeutics' higher probable upside, equities analysts plainly believe BioXcel Therapeutics is more favorable than PureTech Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more volatility and risk, BTAI or PRTC? BioXcel Therapeutics has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Is BTAI or PRTC more profitable? PureTech Health has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-3,119.33% N/A -105.04% PureTech Health N/A N/A N/A Does the MarketBeat Community believe in BTAI or PRTC? BioXcel Therapeutics received 236 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 67.49% of users gave BioXcel Therapeutics an outperform vote while only 45.00% of users gave PureTech Health an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24567.49% Underperform Votes11832.51% PureTech HealthOutperform Votes945.00% Underperform Votes1155.00% Which has higher valuation & earnings, BTAI or PRTC? PureTech Health has higher revenue and earnings than BioXcel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$2.28M3.13-$179.05M-$34.56-0.07PureTech Health$3.33M132.53-$65.70MN/AN/A Do insiders & institutionals have more ownership in BTAI or PRTC? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 0.0% of PureTech Health shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by insiders. Comparatively, 5.3% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor BTAI or PRTC? In the previous week, BioXcel Therapeutics' average media sentiment score of 0.00 equaled PureTech Health'saverage media sentiment score. Company Overall Sentiment BioXcel Therapeutics Neutral PureTech Health Neutral SummaryPureTech Health beats BioXcel Therapeutics on 8 of the 14 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.84M$7.07B$5.80B$8.99BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-0.066.0226.3218.88Price / Sales4.95316.05452.0876.91Price / CashN/A67.8344.0437.47Price / Book-0.076.757.644.66Net Income-$179.05M$138.11M$3.18B$245.69M7 Day Performance-4.55%-1.85%-1.66%-2.22%1 Month Performance-61.50%-1.39%0.41%-1.95%1 Year Performance-95.63%-2.92%17.47%14.12% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.1553 of 5 stars$2.21-4.1%$37.00+1,578.0%-95.9%$6.84M$1.38M-0.0690PRTCPureTech Health2.1966 of 5 stars$18.95flat$45.00+137.5%-29.4%$453.66M$3.33M0.00100Gap UpALTAltimmune2.6485 of 5 stars$6.37+2.2%$20.83+227.1%-21.1%$453.03M$430,000.00-4.1150Short Interest ↓CDXCChromaDex4.4937 of 5 stars$5.87+5.2%$8.00+36.3%+258.5%$448.35M$83.57M587.59120News CoverageKMDAKamada4.0947 of 5 stars$7.78-2.1%$14.50+86.4%+26.0%$447.19M$142.52M27.79360High Trading VolumeMREOMereo BioPharma Group2.955 of 5 stars$2.87-0.3%$7.83+172.9%-19.8%$445.28M$10M0.0040ERASErasca2.2021 of 5 stars$1.57-3.7%$5.70+263.1%-25.9%$443.88MN/A-1.89120Gap UpTKNOAlpha Teknova0.9453 of 5 stars$8.28+1.0%$8.50+2.7%+160.7%$441.39M$36.35M-11.19240SIGASIGA Technologies1.4861 of 5 stars$6.14+1.5%N/A+20.7%$438.40M$139.92M5.1240Options VolumeNews CoverageSAGESage Therapeutics4.7205 of 5 stars$7.14-0.6%$9.65+35.1%-67.7%$436.75M$86.46M-1.28690ZVRAZevra Therapeutics1.9205 of 5 stars$8.07+1.0%$21.57+167.3%+13.6%$430.78M$27.46M-4.1020 Related Companies and Tools Related Companies PureTech Health Alternatives Altimmune Alternatives ChromaDex Alternatives Kamada Alternatives Mereo BioPharma Group Alternatives Erasca Alternatives Alpha Teknova Alternatives SIGA Technologies Alternatives Sage Therapeutics Alternatives Zevra Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BTAI) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
